Entera Bio Ltd. EPS (Basic)

EPS (Basic) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic) growth rates and interactive chart. Basic earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of basic shares outstanding (doesn't take into account potential dilution from options or share issuance).

Highlights and Quick Summary

  • EPS (Basic) for the quarter ending June 29, 2020 was -0.17 (a 6.25% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Basic) decreased by -32.0%
  • Annual EPS (Basic) for 2019 was -0.89 (a -31.54% decrease from previous year)
  • Twelve month EPS (Basic) ending June 29, 2020 was -0.84 (a 6.33% increase compared to previous quarter)
  • Twelve month trailing EPS (Basic) increased by 5.0% year-over-year
Trailing EPS (Basic) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-0.84 -0.79 -0.89 -0.8
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic) of Entera Bio Ltd.

Most recent EPS (Basic)of ENTX including historical data for past 10 years.

Interactive Chart of EPS (Basic) of Entera Bio Ltd.

Entera Bio Ltd. EPS (Basic) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.17 -0.16
2019 -0.26 -0.25 -0.12 -0.26 -0.89
2018 -0.17 -0.45 -45.25 -1.3

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.